Evidence map›Paper›PMID 40558112›Full record

ReviewAdvances in respiratory medicine2025

Efficacy and Safety of

Verena M Merk, Georg Boonen, Veronika Butterweck, Andreas Schapowal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Viruses · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Verena M MerkMedical Department, Max Zeller Söhne AG, 8590 Romanshorn, Switzerland.
Georg BoonenMedical Department, Max Zeller Söhne AG, 8590 Romanshorn, Switzerland.
Veronika ButterweckMedical Department, Max Zeller Söhne AG, 8590 Romanshorn, Switzerland.ORCID 0000-0001-7516-8789
Andreas SchapowalSchweizerische Medizinische Gesellschaft für Phytotherapie, 8021 Zurich, Switzerland.ORCID 0000-0002-7270-2154

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis (AR) is a global health problem on the rise. More and more people are affected, and climate change is exacerbating this health problem in the long term. The quality of life of those affected is often severely compromised, and the financial burden on healthcare systems cannot be disregarded. Therefore, effective and safe medicines are needed to counteract this trend.

Indexed as

PhytotherapyPlant ExtractsRhinitis, AllergicHumansPlant LeavesPlant Extractsallergic rhinitisbutterburhay feverPetasites hybridussafetyZe 339

Identifiers

PMID40558112
PMCPMC12189244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.